Drug Information

Drug General Information
Drug ID
D02ENH
Former ID
DNC008744
Drug Name
(R)-Norfluoxetine
Drug Type
Small molecular drug
Indication Discovery agent Investigative [529814]
Formula
C16H16F3NO
Canonical SMILES
C1=CC=C(C=C1)C(CCN)OC2=CC=C(C=C2)C(F)(F)F
InChI
1S/C16H16F3NO/c17-16(18,19)13-6-8-14(9-7-13)21-15(10-11-20)12-4-2-1-3-5-12/h1-9,15H,10-11,20H2/t15-/m1/s1
InChIKey
WIQRCHMSJFFONW-OAHLLOKOSA-N
PubChem Compound ID
9797657
Target and Pathway
Target(s) Sodium-dependent dopamine transporter Target Info Inhibitor [529814]
Sodium-dependent serotonin transporter Target Info Inhibitor [529814]
Sodium-dependent noradrenaline transporter Target Info Inhibitor [529814]
KEGG Pathway Dopaminergic synapse
Parkinson's disease
Cocaine addiction
Amphetamine addiction
Alcoholismhsa04726:Serotonergic synapse
NetPath Pathway TCR Signaling Pathway
PANTHER Pathway Adrenaline and noradrenaline biosynthesis
Parkinson disease
Dopamine receptor mediated signaling pathwayP04373:5HT1 type receptor mediated signaling pathway
5HT2 type receptor mediated signaling pathway
5HT3 type receptor mediated signaling pathway
5HT4 type receptor mediated signaling pathwayP00001:Adrenaline and noradrenaline biosynthesis
Pathway Interaction Database Alpha-synuclein signaling
Reactome Na+/Cl- dependent neurotransmitter transportersR-HSA-442660:Na+/Cl- dependent neurotransmitter transporters
WikiPathways Monoamine Transport
NRF2 pathway
Dopaminergic Neurogenesis
Parkinsons Disease Pathway
Transport of glucose and other sugars, bile salts and organic acids, metal ions and amine compounds
Neurotransmitter Clearance In The Synaptic CleftWP727:Monoamine Transport
SIDS Susceptibility Pathways
Synaptic Vesicle Pathway
Serotonin Transporter ActivityWP727:Monoamine Transport
References
Ref 529814Bioorg Med Chem. 2009 Jan 1;17(1):337-43. Epub 2008 Nov 5.Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression.
Ref 529814Bioorg Med Chem. 2009 Jan 1;17(1):337-43. Epub 2008 Nov 5.Stereoselective inhibition of serotonin re-uptake and phosphodiesterase by dual inhibitors as potential agents for depression.